公开(公告)号：US11866418B2

公开(公告)日：2024-01-09

申请号：US17730438

申请日：2022-04-27

Applicant: BioCryst Pharmaceuticals, Inc.

Inventor： Pravin L. Kotian ,  Yarlagadda S. Babu ,  Weihe Zhang ,  Peng-Cheng Lu ,  Minwan Wu ,  Wei Lv ,  Trung Xuan Nguyen ,  Zhao Dang ,  Venkat R. Chintareddy ,  V. Satish Kumar ,  Krishnan Raman

IPC: C07D401/10 ,  C07D209/12 ,  C07D261/20 ,  C07D307/80 ,  C07D333/64 ,  C07D401/12 ,  C07D405/10

CPC classification number: C07D401/10 ,  C07D209/12 ,  C07D261/20 ,  C07D307/80 ,  C07D333/64 ,  C07D401/12 ,  C07D405/10

Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

公开(公告)号：US11708347B2

公开(公告)日：2023-07-25

申请号：US17168574

申请日：2021-02-05

Applicant: BioCryst Pharmaceuticals, Inc.

Inventor： Pravin L. Kotian ,  Yarlagadda S. Babu ,  Weihe Zhang ,  Peng-Cheng Lu ,  Minwan Wu ,  Wei Lv ,  Trung Xuan Nguyen ,  Zhao Dang ,  Venkat R. Chintareddy ,  V. Satish Kumar ,  Krishnan Raman

IPC: C07D401/10 ,  C07D209/12 ,  C07D261/20 ,  C07D307/80 ,  C07D333/64 ,  C07D401/12 ,  C07D405/10

CPC classification number: C07D401/10 ,  C07D209/12 ,  C07D261/20 ,  C07D307/80 ,  C07D333/64 ,  C07D401/12 ,  C07D405/10

Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

公开(公告)号：US20240376117A1

公开(公告)日：2024-11-14

申请号：US18647310

申请日：2024-04-26

Applicant: BioCryst Pharmaceuticals, Inc.

Inventor： Pravin L. Kotian ,  Yarlagadda S. Babu ,  V. Satisha Kumar ,  Weihe Zhang ,  Peng-Cheng Lu ,  Krishnan Raman

IPC: C07D491/048 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04 ,  C07D513/04

Abstract: Disclosed are compounds of formula I, II, III, and IV, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of ALK2 kinase. Also provided are pharmaceutical compositions comprising a compound of formula I, II, III, or IV, or pharmaceutically acceptable salt thereof, and methods involving use of the compounds or pharmaceutically acceptable salts thereof and compositions in the treatment and prevention of various diseases and conditions, such as fibrodysplasia ossificans progressiva.

公开(公告)号：US20240294494A1

公开(公告)日：2024-09-05

申请号：US18407053

申请日：2024-01-08

Applicant: BioCryst Pharmaceuticals, Inc

Inventor： Pravin L. Kotian ,  Yarlagadda S. Babu ,  Weihe Zhang ,  Peng-Cheng Lu ,  Minwan Wu ,  Wei Lv ,  Trung Xuan Nguyen ,  Zhao Dang ,  Venkat R. Chintareddy ,  V. Satish Kumar ,  Krishnan Raman

IPC: C07D401/10 ,  C07D209/12 ,  C07D261/20 ,  C07D307/80 ,  C07D333/64 ,  C07D401/12 ,  C07D405/10

CPC classification number: C07D401/10 ,  C07D209/12 ,  C07D261/20 ,  C07D307/80 ,  C07D333/64 ,  C07D401/12 ,  C07D405/10

Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

公开(公告)号：US20240270750A1

公开(公告)日：2024-08-15

申请号：US18562115

申请日：2022-05-24

Applicant: BioCryst Pharmaceuticals, Inc.

Inventor： Pravin L. Kotian ,  Yarlagadda S. Babu ,  Weihe Zhang ,  Wei Lv ,  Peng-Cheng Lu ,  Andrew E. Spaulding ,  Krishnan Raman

IPC: C07D487/04 ,  A61K31/517 ,  A61K31/519 ,  A61K31/52 ,  A61K31/53 ,  C07D403/12 ,  C07D471/04 ,  C07D473/34 ,  C07D491/048 ,  C07D495/04 ,  C07D513/04

CPC classification number: C07D487/04 ,  A61K31/517 ,  A61K31/519 ,  A61K31/52 ,  A61K31/53 ,  C07D403/12 ,  C07D471/04 ,  C07D473/34 ,  C07D491/048 ,  C07D495/04 ,  C07D513/04

Abstract: Disclosed are compounds of formula I, II, III, and IV, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of ALK2 kinase. Also provided are pharmaceutical compositions comprising a compound of formula I, II, III, or IV, or pharmaceutically acceptable salt thereof, and methods involving use of the compounds or pharmaceutically acceptable salts thereof and compositions in the treatment and prevention of various diseases and conditions, such as fibrodysplasia ossificans progressiva.

公开(公告)号：US20230099716A1

公开(公告)日：2023-03-30

申请号：US17730438

申请日：2022-04-27

Applicant: BioCryst Pharmaceuticals, Inc.

Inventor： Pravin L. Kotian ,  Yarlagadda S. Babu ,  Weihe Zhang ,  Peng-Cheng Lu ,  Minwan Wu ,  Wei Lv ,  Trung Xuan Nguyen ,  Zhao Dang ,  Venkat R. Chintareddy ,  V. Satish Kumar ,  Krishnan Raman

IPC: C07D401/10 ,  C07D209/12 ,  C07D261/20 ,  C07D307/80 ,  C07D333/64 ,  C07D401/12 ,  C07D405/10

Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

公开(公告)号：US11021458B2

公开(公告)日：2021-06-01

申请号：US16511642

申请日：2019-07-15

Applicant: BioCryst Pharmaceuticals, Inc.

Inventor： Pravin L. Kotian ,  Yarlagadda S. Babu ,  Weihe Zhang ,  Peng-Cheng Lu ,  Minwan Wu ,  Wei Lv ,  Trung Xuan Nguyen ,  Zhao Dang ,  Venkat R. Chintareddy ,  V. Satish Kumar ,  Krishnan Raman

IPC: C07D401/10 ,  C07D209/12 ,  C07D261/20 ,  C07D307/80 ,  C07D333/64 ,  C07D401/12 ,  C07D405/10

Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.